IM Cannabis (IMCC) Competitors $1.97 -0.11 (-5.29%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends IMCC vs. CVKD, COCP, BFRG, TXMD, NERV, CARA, SYBX, GLMD, MRNS, and GOVXShould you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Cadrenal Therapeutics (CVKD), Cocrystal Pharma (COCP), Bullfrog AI (BFRG), TherapeuticsMD (TXMD), Minerva Neurosciences (NERV), Cara Therapeutics (CARA), Synlogic (SYBX), Galmed Pharmaceuticals (GLMD), Marinus Pharmaceuticals (MRNS), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry. IM Cannabis vs. Cadrenal Therapeutics Cocrystal Pharma Bullfrog AI TherapeuticsMD Minerva Neurosciences Cara Therapeutics Synlogic Galmed Pharmaceuticals Marinus Pharmaceuticals GeoVax Labs Cadrenal Therapeutics (NASDAQ:CVKD) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership. Does the MarketBeat Community favor CVKD or IMCC? IM Cannabis received 1 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 42.86% of users gave IM Cannabis an outperform vote. CompanyUnderperformOutperformCadrenal TherapeuticsOutperform Votes5100.00% Underperform VotesNo VotesIM CannabisOutperform Votes642.86% Underperform Votes857.14% Is CVKD or IMCC more profitable? Cadrenal Therapeutics has a net margin of 0.00% compared to IM Cannabis' net margin of -26.46%. Cadrenal Therapeutics' return on equity of -93.70% beat IM Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets Cadrenal TherapeuticsN/A -93.70% -82.23% IM Cannabis -26.46%-97.26%-25.27% Do analysts recommend CVKD or IMCC? Cadrenal Therapeutics currently has a consensus target price of $3.50, indicating a potential downside of 80.11%. Given Cadrenal Therapeutics' higher possible upside, research analysts clearly believe Cadrenal Therapeutics is more favorable than IM Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00IM Cannabis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the media favor CVKD or IMCC? In the previous week, Cadrenal Therapeutics had 2 more articles in the media than IM Cannabis. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 0 mentions for IM Cannabis. Cadrenal Therapeutics' average media sentiment score of 0.00 equaled IM Cannabis'average media sentiment score. Company Overall Sentiment Cadrenal Therapeutics Neutral IM Cannabis Neutral Do insiders & institutionals have more ownership in CVKD or IMCC? 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 48.6% of Cadrenal Therapeutics shares are owned by company insiders. Comparatively, 5.9% of IM Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, CVKD or IMCC? Cadrenal Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Which has higher earnings and valuation, CVKD or IMCC? IM Cannabis has higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCadrenal TherapeuticsN/AN/A-$8.36M-$5.55-3.17IM Cannabis$36.15M0.12-$7.04M-$3.83-0.51 SummaryCadrenal Therapeutics beats IM Cannabis on 9 of the 15 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get IM Cannabis News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCC vs. The Competition Export to ExcelMetricIM CannabisMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.39M$1.32B$5.40B$8.53BDividend YieldN/AN/A5.15%4.14%P/E Ratio-0.517.27113.7615.14Price / Sales0.128.121,483.0493.53Price / CashN/A15.7539.7134.04Price / Book0.432.094.665.01Net Income-$7.04M-$52.95M$119.06M$225.46M7 Day Performance-5.34%-0.54%0.79%0.37%1 Month Performance-14.35%6.49%5.65%3.57%1 Year Performance-30.53%11.77%36.80%29.42% IM Cannabis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCCIM Cannabis0.3972 of 5 stars$1.97-5.3%N/A-29.1%$4.39M$36.15M-0.51340Positive NewsGap UpCVKDCadrenal Therapeutics0.8392 of 5 stars$16.96+3.5%$3.50-79.4%N/A$18.11MN/A-3.064COCPCocrystal Pharma2.7036 of 5 stars$1.77-2.2%$7.00+295.5%+4.2%$18.01MN/A-1.0010BFRGBullfrog AI1.19 of 5 stars$2.28-3.0%N/A-14.9%$17.90M$65,000.00-2.714Gap UpTXMDTherapeuticsMD0.8331 of 5 stars$1.55flatN/A-26.1%$17.88M$996,000.000.00420NERVMinerva Neurosciences4.0737 of 5 stars$2.40-1.6%$5.00+108.8%-47.6%$16.99MN/A-0.549Upcoming EarningsAnalyst ForecastNews CoverageCARACara Therapeutics4.1333 of 5 stars$0.31+6.9%$2.32+647.4%-75.5%$16.97M$11.00M-0.1555News CoverageHigh Trading VolumeSYBXSynlogic2.7858 of 5 stars$1.44-1.4%$30.00+1,983.3%-16.6%$16.86M$3.17M-0.2180News CoveragePositive NewsGLMDGalmed Pharmaceuticals1.7527 of 5 stars$3.34-4.6%N/A-32.5%$16.85MN/A-0.1920MRNSMarinus Pharmaceuticals4.1193 of 5 stars$0.30-6.2%$6.07+1,904.4%-95.1%$16.68M$30.99M-0.11110Upcoming EarningsAnalyst ForecastGOVXGeoVax Labs3.2243 of 5 stars$1.97-2.5%$12.67+543.0%-74.9%$16.52M$300,677.000.0017Positive News Related Companies and Tools Related Companies CVKD Competitors COCP Competitors BFRG Competitors TXMD Competitors NERV Competitors CARA Competitors SYBX Competitors GLMD Competitors MRNS Competitors GOVX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMCC) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IM Cannabis Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share IM Cannabis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
